BRAF and melanoma: For high-risk individuals (stages II B, C, D, and stage III), the mutational analysis of primary tumor or metastases is performed in order to offer adjuvant treatment, i.e., targeted treatment (mainly BRAF and MEK inhibitors for BRAF mutant melanoma) or immune checkpoint inhibitors (ICI).